Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00125125 · ClinicalTrials.gov registry record · Phase 4

Fluvastatin in Adults With Dislipidemia With History of Muscle Problems

A Phase 4 study of Dyslipidemia, sponsored by Novartis.

Completed
Registry status
Phase 4
Development phase
218
Enrollment target
2
Study locations

NCT00125125 is a Phase 4 study of Dyslipidemia that has completed, run by Novartis. The registered enrollment target is 218 participants, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (39% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00125125, a Phase 4 study of Dyslipidemia, has completed, sponsored by Novartis.

COMPLETED
Registry status
Phase 4
Development phase
218 participants
Enrollment target
2
Study locations

Study Summary

The purpose of the study is to find a good therapy for patients who need to be treated for high cholesterol and who have difficulty tolerating other statins (such as pravastatin, simvastatin, lovastatin, atorvastatin, rosuvastatin) due to muscle pain.

Conditions Studied

Interventions

  • DRUG Fluvastatin

Study Locations (2)

New Jersey

  • Novartis - East Hanover

Other

  • - Investigative Centers

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2005-05
Est. Completion 2005-12
Phase Phase 4

Sponsor

Novartis

265 total trials

What the Registry Record Tells You About NCT00125125

The ClinicalTrials.gov registry entry for NCT00125125 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (39% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 1 intervention - of which Fluvastatin is the first listed.

NCT00125125 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.

Frequently Asked Questions

What is clinical trial NCT00125125 about?

NCT00125125 is a clinical study titled "Fluvastatin in Adults With Dislipidemia With History of Muscle Problems". The purpose of the study is to find a good therapy for patients who need to be treated for high cholesterol and who have difficulty tolerating other statins (such as pravastatin, simvastatin, lovastatin, atorvastatin, rosuvastatin) due to muscle pain.

What is the current status of trial NCT00125125?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 218 participants. The study started on 2005-05. Estimated completion is 2005-12.

What conditions does trial NCT00125125 study?

This clinical trial studies the following conditions: Dyslipidemia.

What interventions are being tested in trial NCT00125125?

The interventions under investigation include: Fluvastatin (DRUG).

Who is sponsoring clinical trial NCT00125125?

This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00125125 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dyslipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.